Los Angeles Capital Management & Equity Research Inc. Has $233,000 Holdings in Enzo Biochem, Inc. (ENZ)

Share on StockTwits

Los Angeles Capital Management & Equity Research Inc. trimmed its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 19.6% during the first quarter, HoldingsChannel.com reports. The fund owned 85,523 shares of the medical research company’s stock after selling 20,860 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Enzo Biochem were worth $233,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ENZ. BlackRock Inc. grew its holdings in shares of Enzo Biochem by 0.4% during the fourth quarter. BlackRock Inc. now owns 4,010,279 shares of the medical research company’s stock worth $11,149,000 after purchasing an additional 17,405 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Enzo Biochem by 26.3% during the third quarter. Vanguard Group Inc now owns 2,715,398 shares of the medical research company’s stock worth $11,188,000 after purchasing an additional 565,126 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Enzo Biochem by 26.3% during the third quarter. Vanguard Group Inc. now owns 2,715,398 shares of the medical research company’s stock worth $11,188,000 after purchasing an additional 565,126 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Enzo Biochem by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 2,042,601 shares of the medical research company’s stock worth $8,415,000 after purchasing an additional 40,030 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Enzo Biochem by 6.0% during the fourth quarter. Bank of New York Mellon Corp now owns 218,918 shares of the medical research company’s stock worth $609,000 after purchasing an additional 12,371 shares during the last quarter. Hedge funds and other institutional investors own 67.11% of the company’s stock.

Shares of ENZ stock opened at $3.67 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.38 and a current ratio of 3.83. Enzo Biochem, Inc. has a 52 week low of $2.32 and a 52 week high of $6.89.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Monday, March 11th. The medical research company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $19.33 million for the quarter. Enzo Biochem had a negative return on equity of 29.83% and a negative net margin of 25.55%.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Has $233,000 Holdings in Enzo Biochem, Inc. (ENZ)” was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://macondaily.com/2019/05/16/los-angeles-capital-management-equity-research-inc-has-233000-holdings-in-enzo-biochem-inc-enz.html.

About Enzo Biochem

Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.